Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in the following investor conferences:
- Guggenheim Inaugural Healthcare Innovation Conference (Boston, MA)
Monday, November 11, 2024
Fireside Chat at 11:30 a.m. Eastern Time
- UBS Global Healthcare Conference (Rancho Palos Verdes, CA)
Wednesday, November 13, 2024
Available for 1x1 meetings
Fireside Chat at 9:30 a.m. Pacific Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
[email protected]
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
[email protected]
Investor Contacts:
Lee Roth
Burns McClellan
Phone: 646-382-3403
[email protected]
Julia Weilman
Burns McClellan
Phone: 646-732-4443
[email protected]
This press release was published by a CLEAR® Verified individual.
